Stay informed
MAPS practices the principle of Open Science, Open Books, transparently sharing what we learn. Through our publications, we seek to Be the Bridge, building common knowledge between the medical, the mystical, the marginalized, and the mainstream.
Are you a member of the media? Visit our newsroom.
Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed
November 17, 2022
FOR IMMEDIATE RELEASE: November 17, 2022 MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase …
MAPS Analysis of Colorado’s Natural Medicine Health Act: Reviewing Proposition 122/Measure 58
October 26, 2022
MAPS’ Policy Values Over the last three years since MAPS published our Considerations For the Regulation and Decriminalization of Psychedelic Substances statement, multiple policy approaches to psychedelics …
Statement: Biden Administration Plans to Pardon Prior Federal Offenses of Simple Marijuana Possession
October 6, 2022
Today, the White House released a statement that President Joe Biden “will grant a pardon to all people convicted of simple marijuana possession under federal law” and “urged governors to take similar …
Following Landmark Achievement, California Psychedelic Decriminalization Bill Slated for 2023 Reintroduction
September 1, 2022
Senate Bill 519 would have decriminalized the personal possession of certain psychedelic substances, legalized life-saving public health interventions, and studied future approaches to increasing use of …
MAPS, in Coordination with Allies, Assists U.S. Sentencing Commission in Reaching Quorum
August 17, 2022
United States Sentencing Commission, which establishes and advises Congress on federal sentencing guidelines, reaches first quorum in 3 years and a full slate for first time since 2014 Delayed appointments …
Statement: Biden Administration Preparing for Potential FDA Approval of MDMA-Assisted Therapy for PTSD
July 27, 2022
Yesterday, a letter from the U.S. Department of Health and Human Services was made public describing the Food and Drug Administration’s “anticipated approval…within approximately 24 months” of …
MAPS Launches Psychedelic Fundamentals, an Online Education Curriculum From Leading Psychedelic Organization
July 14, 2022
Psychedelic Fundamentals is the initial offering in the new MAPS Digital Learning program introducing learners to the most important aspects of psychedelic history, research, uses, and harm reduction The …
MAPS Raises Nearly $1.6 Million in Christie’s NFT Auction
June 30, 2022
Historic Curated “Cartography of the Mind: A Curated NFT Sale” Auction is the First Time MAPS has Raised Money Using NFTs Beeple’s PILGRIMAGEPrice Realized: $252,000 Digital art, inspired by personal …
MDMA-Assisted Group Therapy for PTSD Among Veterans Study Will Proceed Following Successful Safety Negotiations
June 29, 2022
The FDA lifted the clinical hold from a MAPS-sponsored Phase 2 study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder among veterans at the VA Portland Health Care System …
Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration
June 27, 2022
On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy in collaboration with MMS Holdings The second Phase 3 trial of the Breakthrough-Designated …
MAPS Appoints Jeff George and Dan Grossman to MAPS PBC Board of Directors
June 7, 2022
Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access Appointment brings significant pharmaceutical leadership experience to the MAPS PBC board …
Christie’s Announces Cartography of the Mind: A Curated NFT Sale to Benefit MAPS
June 6, 2022
Christie’s is pleased to present Cartography of the Mind, a Curated NFT Sale to benefit the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with Ryan Zurrer, founder of …